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NHS monthly costs between overweight (47€), mild (128€),
moderate (162€) and severe (205€) obese subjects was signiﬁcant
(P = 0.02, Kruskall Wallis test). We found no statistically signif-
icant difference in out-of-pocket costs (P = 0.52). CONCLU-
SIONS: In few years the cost for the health care management of
a cohort of more than 5 millions of obese plus 15 millions of
overweight individuals in Italy is likely to become unbearable for
the I-Nhs, as it will be for most health systems. Policy makers
should give the highest priority to the identiﬁcation, promotion
and implementation of effective integrated programmes for the
prevention of obesity and overweight.
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OBJECTIVES: The health service impact of obesity is growing
relentlessly. There exist a small number of medical treatments 
for obesity. Obesity results in an increased risk of a plethora of
diseases. The purpose of this study was to evaluate the cost-
utility of orlistat (Xenical) in the UK. METHODS: A stochastic
simulation model was constructed using clinical trial and real-
life data comparing orlistat with no treatment and placebo under
various scenarios. The time duration was 2-years, 2003 prices
(UK£), costs discounted at 6%, beneﬁts 11/2% and evaluated
from an NHS perspective. Events were determined for only 
cardiovascular (CV) disease end points, and determined by
various risk functions. Utility was gained by a direct reduction
in obesity, survival and progression to CV events, including
microvascular events for diabetes. Costs were summed for events
and maintenance therapies. Extensive statistical economic analy-
sis and sensitivity analysis was undertaken. RESULTS: The cost
per quality adjusted life year (QALY) for orlistat versus no
treatment evaluating National Institute for Clinical Ecxellence
(NICE) guidelines was £12,814. The cost per QALY for orlistat
versus no treatment evaluating the product license was £13,045.
The cost per QALY for orlistat versus placebo evaluating 
NICE guidelines was £19,128. The cost per QALY for orlistat
versus no treatment evaluating the product license was £17,386.
These ﬁndings were fairly insensitive to variation in the main
parameters. CONCLUSIONS: These data, from a conservative
evaluation of the cost-utility of orlistat, showed that the treat-
ment is well within the cost-effectiveness threshold set by 
NICE (£20,000/QALY and £30,000/QALY). This analysis con-
tinues to support the positive guidance made by NICE in 2001
on orlistat.
OBESITY
OBESITY—Quality of Life/Utility/Preference Studies
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OBJECTIVES: Purpose of this study was to evaluate quality of
life (QoL) changes in MAP patients treated with orlistat accord-
ing to the product licence. Orlistat, a clinically-effective, cost-
effective treatment for weight reduction, is endorsed by NICE.
MAP, the patient support programme, is endorsed by the UK
Medicines Partnership project and provides direct support
through trained health care professionals to patients treated with
orlistat. METHODS: Patients starting treatment with orlistat
and enrolled in the MAP programme were recruited into this
study. Quality of life was measured using the 31-item, disease-
speciﬁc IWQOL-Lite: Impact of Weight on Quality of Life ques-
tionnaire comprising ﬁve scales assessing physical function,
self-esteem, sexual life, public distress, work and a total score.
Weight, height and body mass index (BMI) were also collected
at baseline, 3 and 6 months. Effect Size (ES) and Standardized
Response Means (SRM) were used to assess clinically meaning-
ful change for IWQOL-Lite subscales and total score, with values
interpreted as small (0.20–0.50), moderate (0.51–0.80) and large
(> = 0.81). RESULTS: All patients (n = 133) who achieved a
weight reduction of at least 5% at 3 months as stipulated by the
product licence were included in the analyses. Results of this
study showed that these patients achieved clinically meaningful
changes from baseline across all disease-speciﬁc QoL subscales,
with moderate changes from baseline in physical function (ES =
0.61; SRM = 0.77), and moderate to large changes from base-
line in self-esteem (ES = 0.66; SRM = 0.91) and IWQOL-Lite
total score (ES = 0.70; SRM = 0.94). CONCLUSIONS: These
ﬁndings clearly demonstrate that a weight reduction of at least
5% in patients taking orlistat enrolled in the MAP programme
translates into clinically signiﬁcant improvements across all
disease-speciﬁc QoL domains. It can therefore be concluded that
a combination of effective treatment with orlistat and direct
patient support provided by health care professionals through
the MAP programme results in clear beneﬁts for these patients.
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OBJECTIVES: Obesity increases the risk of chronic diseases,
with consequences on social cost and Quality of Life (QoL). Our
objective was to estimate the social cost and QoL in overweight,
obese and severe obese people. METHODS: A Cost-of-Illness
study was conducted from the societal perspective, adopting
three-month retrospective observational period. Data were col-
lected from a population based naturalistic survey investigating
cardiovascular risk factors in adult (40–79y.o.) Italian general
population. We selected normal weight people as control group
(Body Mass Index, BMI = 18.5–24.9), overweight (BMI =
25.0–29.9), obese (BMI = 30.0–34.9) and severe obese (BMI >
35.0) people, interviewed by general practitioners on
clinical/demographic characteristics, direct costs (drugs, hospi-
talisations, specialist visits, diagnostics exams) and indirect costs
(productivity loss). QoL was evaluated with the EQ-5D ques-
tionnaire. RESULTS: Data from 620 people were analyzed
(mean age = 58.2, 46.5% men). Total cost in overweight, obese
or severe obese people was quantiﬁed as twice than in normal
weight people (>200 vs. 111€/person/month). Direct cost
involved more than half of total expense: hospitalizations
accounted for the greatest part of direct cost, followed by drugs,
diagnostic exams, medical visits and laboratory exams. Globally,
the Visual Analogue Scale mean score was higher in overweight
than in normal weight people, and lower in obese and severe
obese people. Most of people reported no problem in “mobil-
ity”, “self care” and “usual activities” (around 90%), with
“pain/discomfort” and “anxiety/depression” (around 50%).
Very few people (<5%) reported extreme problems in any
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domains. Problems with physical component of QoL increased
with BMI increase, while for “pain/discomfort” and
“anxiety/depression”, normal weight and severe obese people
complained more than overweight and obese people. CON-
CLUSIONS: obesity is expensive for the health care system and
society and compromises individuals’ QoL. Policy makers should
pay attention to identiﬁcation, promotion and implementation
of programs aimed at preventing obesity.
OSTEOPOROSIS
OSTEOPOROSIS—Cost Studies
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OBJECTIVE: Hip fracture rates in Taiwan have been reported
to be higher than other Asian countries. The objective of this
analysis was to assess the cost-effectiveness of risedronate 
compared to alendronate in high-risk osteoporotic patients in
Taiwan. METHODS: A fracture-incidence based Markov model
of osteoporosis, where patients transition across states, was used
to estimate cost per fracture averted and cost per QALY gained.
The population included 1000 women aged 65 years with low
bone density and previous vertebral fracture, treated over a life-
time with either risedronate or alendronate. Model inputs spe-
ciﬁc to Taiwan included general population hip fracture rates,
mortality rates, health utilities, and relative risk reduction of
fracture with therapy (from published studies). The launch price
of risedronate was anticipated as 20% higher than alendronate
(risedronate: 16,394NT$/year; risedronate 13,662NT$/year).
Vertebral fracture rates were not available for Taiwan, thus inci-
dence rates were based on US ratios of hip to vertebral fracture.
The cost of fracture was included only for ﬁrst year after frac-
ture since chronic treatment is not routine in Taiwan. RESULTS:
There were 58 fewer hip fractures, 35 fewer vertebral fractures
and 52 more QALYs with risedronate compared to alendronate.
The fracture costs were 15% lower for patients treated with rise-
dronate, however total costs (including drug costs) were higher
(259,358NT$ [risedronate] vs. 227,296NT$ [alendronate]). The
incremental cost was 343,225NT$ (8400€) per any fracture
averted, 552,787NT$ (13,500€) per hip fracture averted, and
617,934NT$ (15.100€) per QALY gained for risedronate com-
pared to alendronate. CONCLUSIONS: Risedronate treatment
for high-risk osteoporotic women may represent a cost-effective
strategy for improving care of patients in Taiwan, despite the fact
that there are fewer downstream costs for treatment of chronic
fracture-related disability.
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OBJECTIVE: Osteoporosis and its related fractures are a major
source of illness and costs. Approximately 2 million post-
menopausal women have osteoporosis in France, resulting in an
annual cost of 1€ billion. This study assessed the clinical and eco-
nomic impact of risedronate therapy in a population of women
with post-menopausal osteoporosis (PMO) using a computer
simulation model. METHODS: A fracture incidence based
Markov model of osteoporosis, where patients transition across
outcome states over time, was used to estimate the incremental
cost per fracture prevented and the cost per QALY gained. The
analysis was conducted for a cohort of women aged 70 years
with low bone mineral density and prevalent vertebral fracture.
The impact of risedronate was assessed over 10 years, with
patients treated for the ﬁrst 5 years. Analyses used French epi-
demiological and cost data (from published literature). Relative
risk reductions with risedronate were set at 60% for hip fracture
and 41% for vertebral fracture. RESULTS: When added costs
are expressed per unit of beneﬁt gained, the results were approx-
imately 15,861€ per hip fracture prevented and 4351€ per 
QALY gained. Without treatment, 760 radiographic vertebral
fractures and 104 hip fractures occurred in a cohort of 1000
patients. Treatment with risedronate reduced the fractures occur-
ring during the treatment period, resulting in a smaller number
of fractures over 10 years: 604 vertebral fractures and 77 hip
fractures. If the analysis were extended to the entire PMO 
population in France, treatment with risedronate could result 
in a reduction of 312,000 vertebral fractures and 54,000 hip
fractures over 10 years. CONCLUSIONS: Analysis on a popu-
lation level demonstrates the magnitude of fractures and the cost
savings that could be averted among French women. Using
country-speciﬁc data, simulation models can provide realistic
estimates of the impact of disease and treatment costs in a 
population.
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OBJECTIVES: This study assesses disease burden and treatment
costs in patients with Paget’s Disease (PD) compared with a
matched comparator group (MC). METHODS: This is an obser-
vational study using 2001–2002 MarketScan Research databases
(MEDSTAT, Ann Arbor, MI), which consist of medical claims,
prescriptions and encounter data on 2 million active and retired
USA employees. Details include age, gender, drugs prescribed,
medical services rendered, ICD-9 diagnostic codes and costs. We
linked annual ﬁles to create a longitudinal panel with 24 months
of observation. Persons with PD were identiﬁed by ICD-9 code
731.0. A MC was selected using gender, age and risk adjustment
score, which was derived from a DCG/HCC classiﬁcation system
based on presence of 189 medical conditions. In this analysis, we
calculated the prevalence of 30 conditions linked to PD and total
costs for all medical care. The prevalence of co-morbidities and
health care costs were compared in PD and MC, and differences
tested using chi-square and t-tests, as appropriate. RESULTS:
Our study identiﬁed 488 individuals, 244 with PD and 244
matched comparators (MC). The average age was 72.7 years;
50.8% were female. Largest differences in co-morbidities
detected between PD patients and MC were: pathological frac-
tures (4.9% vs. 0.4%), heart murmurs (3.3% vs. 0.4%), frac-
tures of femur other than neck (2.9% vs. 0.4), spinal stenosis
(2.5% vs. 0.4%), hypercalcemia (1.6% vs. 0.4%), and bone neo-
plasms (7.8% vs. 2.5%), respectively. Annual per patient outpa-
